Physician profile
Sandra A Ford
NPI 1447318357
$2,660.27
in general payments reported to CMS, 2019-2025
28 companies · $644 in 2025
The $644 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $193 · 2021: $299 · 2022: $377 · 2023: $192 · 2024: $480 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $353.14 | 2020-2025 | Zepbound, Jardiance, Kisunla |
| Astrazeneca Pharmaceuticals Lp | $294.03 | 2019-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $241.15 | 2022-2025 | Freestyle Libre 3 |
| Eisai INC. | $229.83 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $228.12 | 2019-2023 | |
| Hikma Pharmaceuticals USA | $157.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $128.02 | 2019-2021 | |
| Novo Nordisk INC | $119.89 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $83.88 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $83.73 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.85 | 2019-2023 | Trijardy Xr, Synjardy, Jardiance |
| Corcept Therapeutics | $72.78 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $64.85 | 2022-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $64.19 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $63.16 | 2021-2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $54.56 | 2024-2025 | Rexulti |
| Amgen INC. | $54.24 | 2019 | |
| Merck Sharp & Dohme LLC | $49.92 | 2022 | |
| Xeris Pharmaceuticals, INC. | $31.77 | 2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $25.67 | 2024 | |
| Lundbeck LLC | $23.00 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $20.58 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.30 | 2020 | |
| Lifescan, INC. | $16.19 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.13 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.